Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade

Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: الهام شیخ ساران , پریسا شیری آقباش , حامد ابراهیم زاده لیل آبادلو , حسین بنازاده باغی , احسان مرادیان , محدثه بهمنی

کلمات کلیدی: Anti-interleukin-6, COVID-19, Inflammation, Interleukin-6, Interleukin-6 receptor, SARS-CoV-2

نشریه: 0 , 3 , 11 , 2022

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله حسین بنازاده باغی
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه بیماری های عفونی و گرمسیری
کد مقاله 79155
عنوان فارسی مقاله Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade
عنوان لاتین مقاله Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade
ناشر 9
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ خیر
عنوان نشریه (خارج از لیست فوق) World Journal of Virology
نوع مقاله Review Article
نحوه ایندکس شدن مقاله ایندکس شده سطح دو – PubMed
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Since December 2019, a novel coronavirus that represents a serious threat to human lives has emerged. There is still no definite treatment for severe cases of the disease caused by this virus, named coronavirus disease 2019 (COVID-19). One of the most considered treatment strategies targets the exaggerated immune regulator, and interleukin (IL)-6 is a crucial pro-inflammatory mediator. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases show an elevated level of IL-6 related to disease severity. IL-6 activity can be inhibited by the following: IL-6 itself, IL-6 signaling pathways such as Janus kinase and signal transducer and activator of transcription (JAK-STAT), gp130, IL-6R, and downstream activated ILs, such as IL-17 and IL-6 cytokine. Currently, according to these studies and their results, IL-6 blockade with anti-IL-6 or its receptor antibodies such as tocilizumab in COVID-19 is beneficial in severe cases and may reduce the mortality rate. JAK-STAT inhibitors block the cytokine storm by inhibiting several crucial pro-inflammatory mediators such as TNF-α and IL-6 and have shown various results in clinical trials. IL-6 induces IL-17 secretion, and IL-17 is involved in the pathogenesis of inflammatory processes. Clinical trials of anti-IL-17 drugs are currently recruiting, and anti-gp130 antibody is preclinical. However, this agent has shown positive effects in inflammatory bowel disease clinical trials and could be tested for SARS-CoV-2. This study aimed to review the role of IL-6 in the cytokine storm and studies regarding IL-6 and blockade of its inflammatory pathways in COVID-19 to determine if any of these agents are beneficial for COVID-19 patients. Bahmani M, Chegini R, Ghanbari E, Sheykhsaran E, Shiri Aghbash P, Leylabadlo HE, Moradian E, Kazemzadeh Houjaghan AM, Bannazadeh Baghi H. Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade. World J Virol 2022; 11(3): 113-128 [PMID: 35665236 DOI: 10.5501/wjv.v11.i3.113]

نویسندگان
hide/show

نویسنده نفر چندم مقاله
الهام شیخ سارانچهارم
پریسا شیری آقباشپنجم
حامد ابراهیم زاده لیل آبادلوششم
حسین بنازاده باغینهم
احسان مرادیانهفتم
محدثه بهمنیاول

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
Severe acute respiratory syndrome coronavirus 2 infection Role of interleukin6 and the inflammatory cascade.pdf1401/04/282636161دانلود